
Publikationen von Roland T. Ullrich
Alle Typen
Zeitschriftenartikel (32)
1.
Zeitschriftenartikel
42, 101085 (2020)
Hepatic FTO is dispensable for the regulation of metabolism but counteracts HCC development in vivo. Molecular Metabolism 2.
Zeitschriftenartikel
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology 3.
Zeitschriftenartikel
6 (36), S. 38458 - 38468 (2015)
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget 4.
Zeitschriftenartikel
74 (10), S. 2816 - 2824 (2014)
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Research 5.
Zeitschriftenartikel
4 (4), S. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery 6.
Zeitschriftenartikel
4 (2), S. 246 - 257 (2014)
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery 7.
Zeitschriftenartikel
134 (12), S. 2829 - 2840 (2014)
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. International Journal of Cancer 8.
Zeitschriftenartikel
123 (4), S. 1732 - 1740 (2013)
Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation 9.
Zeitschriftenartikel
4 (141), 141ra91 (2012)
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translational Medicine 10.
Zeitschriftenartikel
39 (7), S. 1117 - 1127 (2012)
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging 11.
Zeitschriftenartikel
109 (42), S. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 12.
Zeitschriftenartikel
137 (42), S. 2179 - 2180 (2012)
Personalisierte Therapie von Lungenkrebs. Deutsche Medizinische Wochenschrift 13.
Zeitschriftenartikel
10 (6), S. 453 - 459 (2011)
Imaging of non-or very subtle contrast-enhancing malignant gliomas with [ 11C]-methionine positron emission tomography. Molecular Imaging 14.
Zeitschriftenartikel
52 (12), S. 1 - 7 (2011)
Quantitative analysis of response to treatment with Erlotinib in advanced non–small cell lung cancer using 18F-FDG and 39-deoxy-39-18F-fluorothymidine PET. Journal of Nuclear Medicine 15.
Zeitschriftenartikel
6 (5), S. e19592 - e19592 (2011)
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS ONE 16.
Zeitschriftenartikel
84 (Spec. Iss. 2), S. S179 - S195 (2011)
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. British Journal of Radiology 17.
Zeitschriftenartikel
29 (13), S. 1701 - 1708 (2011)
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 18.
Zeitschriftenartikel
143 (2), S. 201 - 211 (2010)
Cytohesins are cytoplasmic ErbB receptor activators. Cell 19.
Zeitschriftenartikel
9 (1), S. 40 - 46 (2010)
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Molecular Imaging 20.
Zeitschriftenartikel
37 (1), S. 84 - 92 (2010)
Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. European Journal of Nuclear Medicine and Molecular Imaging